251 related articles for article (PubMed ID: 33966917)
1. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
Kauffman-Ortega E; Ruiz-Manriquez J; Olivas-Martinez A; Campos-Murguía A; Flores-García NC; Márquez-Guillén E; López-Yáñez S; Sánchez-Ávila F; Toapanta-Yanchapaxi L; Paez-Zayas VM; García-Juárez I
Arch Med Res; 2021 Oct; 52(7):713-718. PubMed ID: 33966917
[TBL] [Abstract][Full Text] [Related]
2. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience.
Araujo A; Valenzuela-Granados V; Lopes AB; Michalczuk MT; Mantovani A; Alvares-da-Silva MR
Ann Hepatol; 2019; 18(3):450-455. PubMed ID: 31028014
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
Manzardo C; Londoño MC; Castells L; Testillano M; Luis Montero J; Peñafiel J; Subirana M; Moreno A; Aguilera V; Luisa González-Diéguez M; Calvo-Pulido J; Xiol X; Salcedo M; Cuervas-Mons V; Manuel Sousa J; Suarez F; Serrano T; Ignacio Herrero J; Jiménez M; Fernandez JR; Giménez C; Del Campo S; Esteban-Mur JI; Crespo G; Moreno A; de la Rosa G; Rimola A; Miro JM;
Am J Transplant; 2018 Oct; 18(10):2513-2522. PubMed ID: 29963780
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.
Bernuth S; Grimm D; Vollmar J; Darstein F; Mittler J; Heise M; Hoppe-Lotichius M; Galle PR; Lang H; Zimmermann T
Drug Des Devel Ther; 2017; 11():2131-2138. PubMed ID: 28744104
[TBL] [Abstract][Full Text] [Related]
6. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care.
Bohorquez H; Bugeaud E; Bzowej N; Scheuermann J; Hand J; Bruce D; Carmody I; Cohen A; Joshi S; Seal J; Sonnier D; Therapondos G; Girgrah N; Anders S; Loss GE
Liver Transpl; 2021 Apr; 27(4):548-557. PubMed ID: 33098277
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
[TBL] [Abstract][Full Text] [Related]
8. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
Peters MG; Kottilil S; Terrault N; Amara D; Husson J; Huprikar S; Florman S; Sulkowski MS; Durand CM; Luetkemeyer AF; Rogers R; Grab J; Haydel B; Blumberg E; Dove L; Emond J; Olthoff K; Smith C; Fishbein T; Masur H; Stock PG
Am J Transplant; 2021 May; 21(5):1780-1788. PubMed ID: 33277801
[TBL] [Abstract][Full Text] [Related]
9. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study.
Jiménez-Romero C; Justo I; Marcacuzco A; García V; Manrique A; García-Sesma Á; Calvo J; Fernández I; Martín-Arriscado C; Caso Ó
Int J Surg; 2021 Jul; 91():105981. PubMed ID: 34098075
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
11. HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.
Emamaullee JA; Bral M; Meeberg G; Montano-Loza AJ; Bain VG; Burak KW; Bigam D; Shapiro AMJ; Kneteman N
Can J Gastroenterol Hepatol; 2019; 2019():2509059. PubMed ID: 30775356
[TBL] [Abstract][Full Text] [Related]
12. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
13. Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Zanaga LP; Santos AG; Ataíde EC; Boin IFSF; Stucchi RSB
Braz J Med Biol Res; 2019; 52(8):e8519. PubMed ID: 31389490
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis.
Liu J; Ma B; Cao W; Li M; Bramer WM; Peppelenbosch MP; Pan Q
Transpl Infect Dis; 2019 Apr; 21(2):e13047. PubMed ID: 30615227
[TBL] [Abstract][Full Text] [Related]
15. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP
Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
19. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
